AZN gets FDA approvable letter (oops—I mean a Complete Response Letter) for Motavizumab: <a href="http://www.reuters.com/article/marketsNews/idINLS22855520081128" target="_blank">http://www.reuters.com/article/marketsNews/idINLS22855520081128</a> Motavizumab is the next-generation version of the blockbuster Synagis. When was the last time the FDA granted a full-fledged approval on the first review cycle? I’m seriously having a hard time remembering.